Form 4: MapLight Therapeutics Director Receives Stock Grant and Option

Nanna Liebach, a Director at MapLight Therapeutics, Inc., was granted restricted stock units and a stock option on June 23, 2026, as part of the company's non-employee director compensation policy.

Summary

• Nanna Liebach, a Director at MapLight Therapeutics, Inc., received a grant of 3,932 restricted stock units (RSUs) on June 23, 2026.
• These RSUs are part of the company's 2025 Equity Incentive Plan and will vest on June 23, 2027, or the date of the company's next annual stockholder meeting, whichever comes first, provided continuous service is maintained.
• Additionally, on the same date, Liebach was granted a stock option to purchase 14,902 shares of common stock at an exercise price of $28.64.
• This stock option also vests on June 23, 2027, or the company's next annual stockholder meeting, subject to continued service.
• Both the RSUs and the stock option were awarded under the company's non-employee director compensation policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard director compensation and does not provide new financial performance data or strategic shifts.

Positives

• Director compensation aligns with equity incentives, potentially aligning director interests with shareholder value.
• Grant of RSUs and stock options indicates continued investment in leadership and potential future growth.

Risks

• Vesting is contingent on continued service, meaning the director could forfeit these awards if they leave the company before the vesting date.
• The stock option has an exercise price of $28.64, meaning the stock price needs to appreciate significantly for the option to be profitable.

Future Outlook

The future outlook is tied to the vesting of the granted equity awards, which are contingent on the reporting person's continued service and the company's performance, as indicated by the vesting schedule tied to the next annual stockholder meeting.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to attract and retain experienced leadership while aligning their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grants align director incentives with long-term company performance, potentially benefiting shareholders if the stock price increases.
• Employees: Standard practice for director compensation, unlikely to have a direct impact on employees.
• Management: Reinforces the company's compensation structure for its board members.

Next Steps

• Continued service by Nanna Liebach to meet vesting requirements for RSUs and stock options.
• Potential exercise of stock options if the stock price exceeds the exercise price of $28.64 after vesting.
• The company's next annual stockholder meeting will determine the final vesting date for the equity awards.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, Stock Options, Equity Incentive Plan, Beneficial Ownership